When cancer is detected early, before it has spread, treatment is generally more effective, and patients have a better chance of long-term survival and improved quality of life.
When cancer is found at a late stage, survival rates are significantly lower as treatment becomes less effective.
Multi-cancer early detection (MCED) diagnostics are shaping the future of cancer detection, offering the ability to identify multiple cancer types through a single, minimally invasive test, often before symptoms arise. This approach increases the chances of early diagnosis, when treatment is most effective, improving survival rates and reducing the overall burden of cancer.
miONCO leverages blood as its liquid biopsy medium for its simplicity, minimally invasiveness, and rich diagnostic potential. Blood provides a comprehensive, system-wide snapshot, capturing circulating biomarkers such as tumor DNA, RNA, proteins, immune signals, and microRNAs (miRNAs). Among these, miRNAs are especially powerful due to their stability and ability to reflect disease-specific gene regulation, making them ideal for early detection and cancer classification. Together, MCED and blood-based liquid biopsy represent a transformative shift, moving diagnosis from late-stage intervention to early-stage prevention significantly improving survival.
MicroRNAs (miRNAs) are tiny molecules in our cells that help regulate which proteins are produced. They do this by attaching to messenger RNA, the genetic instructions for building proteins and blocking or reducing protein production. This regulation is essential for maintaining balanced cell growth, development, and other vital processes. When miRNAs are disrupted or misregulated, it can contribute or be a symptom of diseases such as cancer.
Xgenera’s technology uses a precisely selected panel of miRNAs to detect cancer at its earliest stages. This panel captures signals from the tumour, the body’s response, and the biological drivers of growth. With machine learning, these signals are interpreted to not only predict the presence of cancer but also determine its likely location in the body.
Almost half of all cancers are found at stage 3 and stage 4 where survival rates are significantly lower.
Xgenera understand the importance of early cancer diagnosis and have developed a multi-cancer early diagnostic test to help give people the best chances of survival.
miONCO can detect up to 12 different cancer types in just a single test.
Initial studies have indicated a sensitivity and specificity of greater than 99%.
